Soberlink announced that they have received 510(K) premarket clearance from the Food and Drug Administration (FDA) for their remote breathalyzing monitor, Soberlink Breathalyzer.
The device is intended for medical use by healthcare providers to remotely measure alcohol in human breath, for the purpose of aiding in the detection and monitoring of alcohol consumption in those who suffer from alcohol use disorders. It works in conjunction with the ‘Sober Sky Web Portal’ to transmit blood alcohol content (BAC) results in real time to treatment providers and/or family and loved ones. Furthermore, facial recognition technology is built into the device, helping confirm the identity of the tester.
Remote testing provides another option from the conventional form of alcohol monitoring through a urinalysis test. “It is about time that we have the same kind of technology to provide personalized, continuing care for alcohol use disorders,” said Tom McLellan, founder of the nonprofit research and development organization Treatment Research Institute.
Remote testing provides another option from the conventional form of alcohol monitoring through a urinalysis test. Wearable monitors and remote monitoring devices have been used by patients and clinicians in diabetes and hypertension care management to inform treatment decisions.
For more information visit Soberlink.com.